Comparative Pharmacology
Head-to-head clinical analysis: BETHKIS versus BRISTAGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETHKIS versus BRISTAGEN.
BETHKIS vs BRISTAGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobramycin, an aminoglycoside antibiotic, binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
4 IU/kg (1 mg/kg) intramuscularly or subcutaneously once weekly for 4 weeks, then a maintenance dose of 2 IU/kg (0.5 mg/kg) once weekly.
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
None Documented
None Documented
Terminal elimination half-life 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
2.5 hours (prolonged to 20-40 hours in renal impairment).
Primarily renal excretion of unchanged drug via glomerular filtration; ~90% of absorbed dose excreted in urine within 24 hours; biliary/fecal elimination <5%.
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic